Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

Novartis curates interactive history of medicine exhibition

Beautiful Medicine highlights nature's role in the past and future ofdevelopment

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

- PMLiVE

Novartis’ Cosentyx off to a flyer in psoriasis

Year-to-date sales reach $140m for recently approved drug

- PMLiVE

Merck and MacroGenics collaborate on immuno-oncology

Evaluates margetuximab with Keytruda for gastric cancer

Bristol-Myers Squibb (BMS) building

BMS pulls ahead of Merck in quarterly PD-1 inhibitor sales

Supports analysts prediction BMS' Opdivo will become market leader

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

Novartis’ Cosentyx on course for new European indications

CHMP recommends its approval to treat ankylosing spondylitis and psoriatic arthritis

Merck & Co reorganises its HCP communities, hands Univadis to Physicians Interactive

Physicians Interactive outlines globalambitions for its newly-expanded network

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

- PMLiVE

Novartis Access Scheme launches in Kenya

Expands affordable treatment options against chronic diseases

Bristol-Myers Squibb (BMS) building

BMS gets OK for broader Opdivo use in lung cancer

US regulator'sdecision allows firm to edge in front of Merck & Co's Keytruda

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links